Surge in up-front biotech licensing payments in 2014; report

1 May 2015

It’s been a very good season for licensing deals among biotech companies, with proof be told from Morrison & Foerster’s (MoFo) BioMeter Index. MoFo has just issued a recap of up-front licensing transactions among life sciences companies for all of 2014, confirming strong industry momentum continuing into the current year.

The average licensing payment tracked by BioMeter for all of 2014 was $58.7 million, a sharp increase from 2013’s average of $33.9 million and the highest median value since MoFo first launched its BioMeter Index in 2006.

Boosted by Merck and Bayer deal

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK